^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

    i
    Other names: V503, 9vHPV, V-503, V 503
    Associations

    News

    Trials
    Company:
    Chongqing Zhifei, Merck (MSD)
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2d
    Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    7d
    URVIVE: Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (clinicaltrials.gov)
    P2, N=50, Recruiting, Universiteit Antwerpen
    Trial initiation date
    |
    TRIP13 (Thyroid Hormone Receptor Interactor 13)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    9d
    URVIVE: Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (clinicaltrials.gov)
    P2, N=50, Recruiting, Universiteit Antwerpen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TRIP13 (Thyroid Hormone Receptor Interactor 13)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    16d
    HPV2-2303: Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (clinicaltrials.gov)
    P2, N=85, Recruiting, Centre Oscar Lambret | Trial completion date: Oct 2031 --> Dec 2031
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    20d
    A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    25d
    Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants (clinicaltrials.gov)
    P2, N=201, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    1m
    2024/4031: Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV) (2024-520140-42-00)
    P2/3, N=984, Not yet recruiting, Institut Gustave Roussy
    New P2/3 trial
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    URVIVE: Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Universiteit Antwerpen
    New P2 trial
    |
    TRIP13 (Thyroid Hormone Receptor Interactor 13)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    The magnitude and durability of neutralizing antibody responses to human papillomavirus vaccine do not depend on DNA sensing pathways. (PubMed, J Virol)
    We confirmed separate lots of the 9vHPV vaccine contained low copy numbers of L1 DNA, but found 9vHPV vaccine-generated antibody responses were not dependent on DNA sensing. This study has thus refined our understanding of potential mechanisms underlying the strong and long-lasting antibody responses to HPV vaccination.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • STING (stimulator of interferon response cGAMP interactor 1) • TLR9 (Toll Like Receptor 9)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    NOVA-HIV: A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV (clinicaltrials.gov)
    P4, N=275, Recruiting, University of British Columbia | N=450 --> 275
    Enrollment change
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial (clinicaltrials.gov)
    P3, N=1099, Completed, Imperial College London | Active, not recruiting --> Completed
    Trial completion
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    COVENANT: HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (clinicaltrials.gov)
    P3, N=536, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Aug 2025
    Trial completion • Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)